(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 23.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.21%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.36%.
Mirum Pharmaceuticals's revenue in 2026 is $521,312,000.On average, 13 Wall Street analysts forecast MIRM's revenue for 2026 to be $39,705,387,402, with the lowest MIRM revenue forecast at $37,254,914,336, and the highest MIRM revenue forecast at $41,665,283,122. On average, 12 Wall Street analysts forecast MIRM's revenue for 2027 to be $48,350,530,870, with the lowest MIRM revenue forecast at $41,987,507,357, and the highest MIRM revenue forecast at $53,335,351,850.
In 2028, MIRM is forecast to generate $60,522,641,851 in revenue, with the lowest revenue forecast at $52,083,263,297 and the highest revenue forecast at $72,409,940,400.